DK361084A - Tigogenin-cellobiosid - Google Patents

Tigogenin-cellobiosid Download PDF

Info

Publication number
DK361084A
DK361084A DK361084A DK361084A DK361084A DK 361084 A DK361084 A DK 361084A DK 361084 A DK361084 A DK 361084A DK 361084 A DK361084 A DK 361084A DK 361084 A DK361084 A DK 361084A
Authority
DK
Denmark
Prior art keywords
tigogenin cellobioside
tigogenin
cellobioside
beta
useful
Prior art date
Application number
DK361084A
Other languages
English (en)
Other versions
DK165839C (da
DK361084D0 (da
DK165839B (da
Inventor
M Rene Malinow
Original Assignee
Oregon Medical Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Medical Res Found filed Critical Oregon Medical Res Found
Publication of DK361084D0 publication Critical patent/DK361084D0/da
Publication of DK361084A publication Critical patent/DK361084A/da
Publication of DK165839B publication Critical patent/DK165839B/da
Application granted granted Critical
Publication of DK165839C publication Critical patent/DK165839C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cephalosporin Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
DK361084A 1984-04-20 1984-07-23 Tigogenin-cellobiosidforbindelser, farmaceutiske praeparater, der indeholder forbindelserne, anvendelse af forbindelserne til fremstilling af et farmaceutisk praeparat samt fremgangsmaade til fremstilling af forbindelserne DK165839C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/602,298 US4602005A (en) 1982-05-17 1984-04-20 Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US60229884 1984-04-20

Publications (4)

Publication Number Publication Date
DK361084D0 DK361084D0 (da) 1984-07-23
DK361084A true DK361084A (da) 1985-10-21
DK165839B DK165839B (da) 1993-01-25
DK165839C DK165839C (da) 1993-06-21

Family

ID=24410793

Family Applications (2)

Application Number Title Priority Date Filing Date
DK361084A DK165839C (da) 1984-04-20 1984-07-23 Tigogenin-cellobiosidforbindelser, farmaceutiske praeparater, der indeholder forbindelserne, anvendelse af forbindelserne til fremstilling af et farmaceutisk praeparat samt fremgangsmaade til fremstilling af forbindelserne
DK014892A DK166213C (da) 1984-04-20 1992-02-06 Tigogenin-cellobiosid-heptaacetatforbindelser og fremgangsmaade til fremstilling heraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK014892A DK166213C (da) 1984-04-20 1992-02-06 Tigogenin-cellobiosid-heptaacetatforbindelser og fremgangsmaade til fremstilling heraf

Country Status (16)

Country Link
US (1) US4602005A (da)
EP (1) EP0159431B1 (da)
JP (1) JPS60224697A (da)
KR (1) KR940002114B1 (da)
AT (1) ATE42959T1 (da)
AU (1) AU580005B2 (da)
CA (1) CA1246544A (da)
DE (1) DE3478114D1 (da)
DK (2) DK165839C (da)
ES (1) ES8601233A1 (da)
FI (2) FI82253C (da)
HU (1) HUT37802A (da)
IE (1) IE58015B1 (da)
NO (1) NO842990L (da)
NZ (1) NZ208961A (da)
ZA (1) ZA845690B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
EP0607245B1 (en) * 1991-10-04 1998-04-22 The Procter & Gamble Company Cholesterol lowering compounds and process for making them
CA2079544A1 (en) * 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
EP0619822A1 (en) * 1991-11-25 1994-10-19 Pfizer Inc. Method for making steroidal peracyl glycosides
US5294703A (en) * 1992-05-01 1994-03-15 Eastman Kodak Company Process for preparing α-D-cellobiose octaacetate
AU4226593A (en) * 1992-06-26 1994-01-24 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
FI946082A7 (fi) * 1992-06-26 1994-12-23 Pfizer Menetelmä steroidisten perasyyliglykosidien valmistamiseksi
WO1994000478A1 (en) * 1992-06-26 1994-01-06 Pfizer Inc. Steroidal beta-o-cellobioside heptaalkanoate process
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
CN1121722A (zh) * 1993-04-28 1996-05-01 美国辉瑞有限公司 螺甾烷基苷结晶-水合物
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
WO1995000158A1 (en) * 1993-06-25 1995-01-05 Bio-Sphere Technology Dietary supplement incorporating beta-sitosterol and pectin
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
EP0737203A1 (en) * 1993-12-28 1996-10-16 Pfizer Inc. Steroidal glycosides
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
EP0782451A1 (en) * 1994-09-20 1997-07-09 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US6150336A (en) * 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
HRP20000638A2 (en) * 1998-03-26 2001-04-30 Phytopharm Plc Steroidal sapogenins and their derivatives for treating alzheimer's disease
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (pt) * 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
JP2004517916A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション ニコチン酸およびその誘導体ならびにステロール吸収阻害剤の併用、および血管適応症の治療
CA2434033A1 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR032403A1 (es) * 2001-01-26 2003-11-05 Schering Corp Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
ES2274013T3 (es) * 2001-01-26 2007-05-16 Schering Corporation Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
DE60220269T2 (de) * 2001-01-26 2008-01-17 Schering Corp. Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
AU2002308778A1 (en) * 2001-05-25 2002-12-09 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
CN101785772A (zh) * 2001-09-21 2010-07-28 先灵公司 使用甾醇吸收抑制剂治疗或预防脉管炎的方法
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
US7560449B2 (en) * 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1606287B1 (en) * 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
WO2004081003A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2003300732A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from chlorophytum nimonii
US7160866B2 (en) 2004-03-22 2007-01-09 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from Chlorophytum nimonii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759171A1 (de) * 1977-12-31 1979-07-12 Roecar Holdings Nv Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
US4242502A (en) * 1979-04-20 1980-12-30 United States Of America Enhancement of cholesterol combining properties of saponins
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Also Published As

Publication number Publication date
ATE42959T1 (de) 1989-05-15
EP0159431B1 (en) 1989-05-10
DK165839C (da) 1993-06-21
US4602005A (en) 1986-07-22
DK361084D0 (da) 1984-07-23
ZA845690B (en) 1986-03-26
JPS60224697A (ja) 1985-11-09
DK14892A (da) 1992-02-06
IE841904L (en) 1985-10-20
FI87792B (fi) 1992-11-13
ES534553A0 (es) 1985-11-16
IE58015B1 (en) 1993-06-16
CA1246544A (en) 1988-12-13
DK166213C (da) 1993-08-16
JPH0456840B2 (da) 1992-09-09
FI842935A0 (fi) 1984-07-23
KR940002114B1 (ko) 1994-03-17
NO842990L (no) 1985-10-21
NZ208961A (en) 1988-01-08
EP0159431A3 (en) 1986-01-08
FI900531A0 (fi) 1990-02-02
FI82253C (fi) 1991-02-11
FI842935L (fi) 1985-10-21
ES8601233A1 (es) 1985-11-16
DK166213B (da) 1993-03-22
FI82253B (fi) 1990-10-31
AU3097784A (en) 1985-10-24
FI87792C (fi) 1993-02-25
AU580005B2 (en) 1988-12-22
EP0159431A2 (en) 1985-10-30
DK165839B (da) 1993-01-25
KR850007432A (ko) 1985-12-04
HUT37802A (en) 1986-02-28
DE3478114D1 (en) 1989-06-15
DK14892D0 (da) 1992-02-06

Similar Documents

Publication Publication Date Title
DK361084A (da) Tigogenin-cellobiosid
IE781619L (en) Phosphonoacyl proline compounds.
FI906045A0 (fi) Kvaevehaltiga spirocykliska foereningar.
IE891379L (en) Benzopyrido piperidine, piperidylidene and piperazine¹compounds
DK399588A (da) Pentasaccharider
NO902394D0 (no) Fremgangsmaate for fremstilling av pyranyl-cyanoguanidin-derivater.
ES8701761A1 (es) Un procedimiento para la preparacion de derivados de podofilotoxina.
LV10422A (lv) Jaunie fluor-naftacendioni to glikozetie atvasinajumi un vinu razosanas panemiens
ATE12932T1 (de) N-naphthoylglycin-derivate.
ATE131061T1 (de) Förderung der osteogenese durch verwendung von vitamin d-derivaten.
WO1993025568A3 (en) Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
JPS5566580A (en) Coumarin derivative, its preparation and antiallergic agent containing the same as effective component
SE7709317L (sv) Sett att framstella 2,9-dioxatricyklo(4,3,1,03,7)-dekaner
EP0574271A3 (da)
DE3781986D1 (de) Substituierte chinoxaline.
CA2032311A1 (en) 2,19-methyleneoxy and 2,19-methylenethio bridged steroids as aromatase and 19-hydroxylase inhibitors
DE59907469D1 (de) Ungesättigte oligophenolcyanate
ATE44144T1 (de) 6h-dibenzo(b,e)(1,4)oxathiepin-verbindungen.
DE69008396D1 (de) Trimethylsilylacetylenverbindungen, ihre Herstellung und ihre Verwendung zur Herstellung von Daunomycinon-Derivaten.
FR2525605B1 (da)
FI850401A0 (fi) Maettade tricykliska kvaevehaltiga dioner saosom medel foer aktivering av fattningsfoeremaogan.

Legal Events

Date Code Title Description
PBP Patent lapsed
PBP Patent lapsed